Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013
Cash flows from operating activities:
Net loss	$ (30,025)		$ (33,923)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Share-based compensation	2,196		2,499
Change in fair value of contingent consideration liability	(5,349)		44,013
Recognition of right to borrow asset	0		(2,800)
Amortization of debt discount, deferred interest and right-to-borrow asset	1,624		766
Amortization of premium (discount) on available-for-sale securities	106		(6)
Depreciation and amortization	2,516		2,511
Gain on disposal of property	0		(15)
Changes in operating assets and liabilities:
Receivables	(879)		(25)
Inventory	(967)		(2,061)
Prepaid expenses and other current assets	(752)		(943)
Accounts payable	(2,097)		1,920
Accrued clinical and other accrued liabilities	412		1,549
Deferred revenues	(540)		(2,186)
Other liabilities	(641)		(1,250)
Net cash (used in) provided by operating activities	(34,396)		10,049
Cash flows from investing activities:
Purchases of available-for-sale securities	(33,131)		(10,642)
Maturities of available-for-sale securities	18,340		2,000
Purchases of property and equipment	(2,542)		(1,488)
Proceeds from sale of property and equipment	0		16
Net cash used in investing activities	(17,333)		(10,114)
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants and exercise of stock options and stock purchase rights	214		6,446
Change in restricted cash	(4,160)		5,051
Payment on contingent consideration liability	(251)		(10,313)
Proceeds from financing obligations, net of issuance costs	50,830		10,000
Payments of financing obligations	(584)		(5,027)
Net cash provided by financing activities	46,049		6,157
Net (decrease) increase in cash and cash equivalents	(5,680)		6,092
Cash and cash equivalents at beginning of period	17,306	[1]	17,715
Cash and cash equivalents at end of period	11,626		23,807
Non cash investing and financing activities:
Value of warrants issued with royalty securitization financing	1,721		0
Value of the beneficial conversion feature related to borrowings against the Teva Note	1,032		3,112
Value of right-to-borrow asset reclassified as debt discount	$ 570		$ 1,293

[1] The condensed consolidated balance sheet at December 31, 2013 has been derived from audited consolidated financial statements at that date.